Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Cancer Science|October 5, 2021
Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trialYoshitaka Narita, Yoshihiro Muragaki, Naoki Kagawa, et al.
Journal of Neuro-Oncology|May 24, 2017
Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers: a multi-center retrospective studyYukihiko Sonoda, Ichiyo Shibahara, Ken-Ichiro Matsuda, et al.
Brain Tumor Pathology|March 21, 2022
Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study GroupKenichiro Asano, Yoji Yamashita, Takahiro Ono, et al.
Neuro-Oncology Practice|November 12, 2016
A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis<sup>†</sup>Motomasa Furuse, Naosuke Nonoguchi, Toshihiko Kuroiwa, et al.
International Journal of Clinical Oncology|November 11, 2024
Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resectionMasayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda, et al.
Magnetic Resonance in Medical Sciences : MRMS : an Official Journal of Japan Society of Magnetic Resonance in Medicine|November 20, 2024
Image-based Re-evaluation of the JCOG0911 Study Focusing on Tumor Volume and Survival, Disease Progression Diagnosis, and Radiomic Prognostication for Newly Diagnosed GlioblastomaManabu Kinoshita, Yasutaka Fushimi, Tomohiko Masumoto, et al.
Cancer Chemotherapy and Pharmacology|December 12, 2012
Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)Soichiro Shibui, Yoshitaka Narita, Junki Mizusawa, et al.
Journal of Neuro-Oncology|March 21, 2018
JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastomaToshihiko Wakabayashi, Atsushi Natsume, Junki Mizusawa, et al.
Journal of Neuro-Oncology|May 6, 2020
Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide aloneAtsushi Natsume, Kosuke Aoki, Fumiharu Ohka, et al.
Neuro-Oncology Advances|December 11, 2024
Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: A multicenter, retrospective cohort studyMasayuki Kanamori, Shunsuke Tsuzuki, Ichiyo Shibahara, et al.
Pageof 8